Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2026)

Amneal Pharmaceuticals' EBT Margin history runs 10 years deep, the most recent figure standing at 11.1% for Q1 2026.

• In Q1 2026, EBT Margin rose 571.0% year-over-year to 11.1%; the TTM figure through Mar 2026 stood at 5.97% (up 392.0% YoY), while the FY2025 annual figure was 4.61%, up 658.0% from the prior year.
• EBT Margin was 11.1% for Q1 2026 at Amneal Pharmaceuticals, up from 6.78% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 11.1% in Q1 2026 to a low of 342.1% in Q1 2022.
• Historically, EBT Margin has averaged 21.65% across 5 years, with a median of 0.48% in 2022.
• The sharpest annual moves came in 2022 and 2023: EBT Margin sank 34513 bps in 2022, then jumped 34041 bps in 2023.
• A 5-year view of EBT Margin shows it stood at 0.48% in 2022, then slumped by 2897 bps to 13.53% in 2023, then jumped by 84 bps to 2.1% in 2024, then surged by 423 bps to 6.78% in 2025, then soared by 64 bps to 11.1% in 2026.
• The last three EBT Margin figures came in at 11.1% (Q1 2026), 6.78% (Q4 2025), and 0.67% (Q3 2025), per Business Quant data.